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Angiogenesis in Hodgkin’s lymphoma
ABSTRACT
Angiogenesis is a multistep process controlled by a number of stimulating and inhibiting factors. Aberrant 
angiogenesis is involved in cancer progression. The best-known elements responsible for regulation of 
angiogenesis are vascular endothelial growth factor, their membrane-bound receptors, and circulating, 
soluble receptors. The major objective of the present review is twofold: firstly, it seeks to explore knowledge 
about angiogenesis in Hodgkin’s lymphoma, and secondly it indicates the necessity and relevance of 
carrying out further research dedicated to this process. Hodgkin’s lymphoma is a proliferative disease 
of the lymphatic system. The process of angiogenesis in Hodgkin’s lymphoma has not been studied 
thoroughly. There is a significant role of paracrine interactions of Hodgkin and Reed-Sternberg cells with 
reactive cells of the immune system, which makes studying the mechanisms of development of Hodgkin’s 
lymphoma more difficult. It has been proven that several angiogenesis-stimulating proteins are expressed 
in Hodgkin and Reed-Sternberg cells both in vitro and in tumour tissue. Moreover, some of these proteins 
are produced by the reactive cells. Vascular endothelial growth factor, basic fibroblast growth factor, and 
hepatic growth factor serum concentrations are elevated in patients with Hodgkin’s lymphoma. The role of 
circulating endothelial progenitor cells in the pathogenesis of Hodgkin’s lymphoma has not been thoroughly 
explained. Similarly, there are no satisfying data on the modulation of the angiogenic potential of the blood 
caused by vascular endothelial growth factor soluble receptors in patients with Hodgkin’s lymphoma. 
Processes controlling angiogenesis in Hodgkin’s lymphoma merit more comprehensive investigation.
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Introduction
The process of angiogenesis, that is to say the 
formation of new blood vessels on the substrate of 
the already existing blood vessels, occurs both under 
physiological conditions and as a part of the patho-
physiology of certain diseases. It is strictly regulated 
by a system of stimulating and inhibiting factors [1, 2]. 
Factors involved in this regulation usually remain in the 
state of equilibrium or slight advantage of inhibition. 
Angiogenesis starts in the case of the predominant influ-
ence stimulation. Under the physiologic conditions, the 
process can be observed during foetal development, 
and in the post-natal period in the process of wound 
healing and the cyclical changes accompanying ovu-
lation and menstruation [2]. There are two processes 
involved in angiogenesis: neoangiogenesis, which is 
the formation of a blood vessel on the basis of existing 
ones in tumour tissue, and vasculogenesis, which is 
the de novo formation of blood vessels. Until recently, 
vasculogenesis was believed to occur solely in the 
foetus. However, evidence exists that it also takes 
place during the process of tumour development when 
endothelial progenitor cells derived from bone marrow 
are involved in the formation of the vascular system of 
the tumour. A suitable stimulation initiates a sequence 
of events in the process of angiogenesis. During the 
process, endothelial cells are separated from each 
other. Vascular permeability increases and the matrix 
metalloproteinases are involved in the breakdown of the 
basement membrane and surrounding structures. This 
facilitates the migration of cells towards angiogenesis 
stimulus, accompanied by endothelial proliferation. 
Subsequently, the prepared cell cord produces lumen 
and the new structure takes the function of a blood ves-
sel [2]. Aberrant angiogenesis, which occurs in some 
chronic inflammatory diseases, diabetic retinopathy, 
and ischaemic diseases of the cardiovascular system, 
plays an important role in the development of cancer.
For some time, the progression of cancer remains 
independent of the formation of new blood vessels. In 
the initial phase, the tumour is made up of approximately 
1 million cells, which have a volume of 1–2 mm3. At 
this stage oxygen, nutrients, and growth factors reach 
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the cells through diffusion [1]. In the subsequent phase, 
insufficient supply of oxygen instigates necrosis of the 
central zones of the tumour, whose growth would not be 
possible without an additional provision of blood, or as 
a consequence of a process referred to as an angiogenic 
switch, wherein cells undergo permanent genetic modi-
fications leading to the uncontrolled production of angio-
genic factors. In this perspective, angiogenesis allows 
progression of cancer. In addition to providing supplies 
of tumour tissue with oxygen and nutrients, this process 
paves the way for the spread of cancer cells in the body.
The role of angiogenesis in cancer 
progression: development of the 
concepts
The first theories indicating that development of 
cancer is angiogenesis-dependent date back to the 
1970s and more precisely the pioneering study of Folk-
man [3]. The article presented observations on induced 
neovascularisation and proliferation of endothelial cells, 
which is required for tumour growth and underscores the 
importance of stimulating the growth of blood vessels 
by tumour cells, which enables further proliferation and 
tumour growth. This concept marked the beginning of 
intensive work dedicated to the understanding of the 
molecules regulating angiogenesis, as well as attempts 
to describe this process on the example of various cancer 
types. The authors anticipated that the research on angio-
genic substances may be relevant for the development of 
potential anticancer therapies. In this way, the formation 
of new blood vessels in tumours could be a therapeutic 
target. Subsequent research confirmed the existence of 
soluble substances that inhibit angiogenesis [4].
Aim of the review on angiogenesis in HL
Data on the process of angiogenesis in Hodgkin’s 
lymphoma (HL) are scarce, and the results of studies 
are often contradictory. The objective of the present 
review is to explore knowledge about angiogenesis in 
HL and to indicate the necessity of carrying out further 
research dedicated to this process.
Search strategy
Electronic searches were performed in PubMed/Med-
line and Google Scholar databases without time lim-
itations and were completed on 17th April 2017. The 
main search strategy used a combination of words 
“Hodgkin lymphoma” or “Hodgkin’s lymphoma” and 
“angiogenesis” OR “angiogenic” OR “proangiogenic” 
OR “anti-angiogenic” OR “vasculogenesis” OR “vascu-
lature” OR “micro-vessels” OR “lymphangiogenesis” 
OR “VEGF” OR “VEGFR” OR “sVEGFR” OR “HIF-1” OR 
“angiogenic” OR “angiopoietin” OR “FGF” OR “SDF-1” 
OR “HGF” OR “PDGF” OR “PlGF” OR “TGF” OR “TNF”. 
Searched results including references were then studied 
manually for additional information. No language restric-
tions were applied. Searches were collated, checked 
for duplicates, and sorted by the first author. Results 
were discussed and selected for this review by the first 
author and co-authors.
Angiogenesis regulating factors
Presently there are many known factors involved in 
the regulation of angiogenesis, and the list is constantly 
expanding [1]. The list of proangiogenic and antiangio-
genic factors is shown in Table 1.
Role of the vascular endothelial growth factor and 
its receptors
Vascular endothelial growth factor (VEGF) and its 
receptors (VEGFR) are the best-known elements that 
stimulate angiogenesis. VEGF exists in several isoforms 
resulting from alternative splicing. VEGF stimulates 
the migration and mitosis of vascular endothelial cells 
and increases the capillary permeability. In this way, it 
controls at least some steps of the process that initi-
ates “sprouting” of the new blood vessels. Adhesion of 
individual endothelial cells with each other is reduced 
by the action of VEGFR via cadherin phosphorylation 
and internalisation. VEGF gene expression is regulated 
by the HIF transcription factor (hypoxia-induced factor) 
and the tumour suppressor gene von Hippel-Lindau in 
response to the insufficient level of oxygen supply [5]. 
VEGF-A binds to the membrane-bound receptors VEG-
FR-1 and VEGFR-2 localised on the surface of vascular 
endothelial cells. VEGFR-2 mediates almost all known 
cellular responses to VEGF. The activation of tyrosine 
kinase in these receptors starts a cascade of intracellular 
signalling, which eventually affects the above-mentioned 
effects of VEGF. The vascular endothelial growth factor 
can further mobilise bone marrow endothelial progenitor 
cells and other cells of the myeloid lineage to settle in 
vasculogenesis [2, 6]. VEGF-C and VEGF-D are primarily 
associated with lymphangiogenesis by interaction with 
the endothelial receptors VEGFR-3 and VEGFR-2 [7].
Methods used in studies concerning 
cancer angiogenesis
There are several methods described, whose major 
objective is to expand the knowledge about angiogene-
sis, including measuring the concentration of regulating 
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Table 1. Factors involved in angiogenesis [1]
Proangiogenic factors Antiangiogenic 
factors
aFGF (acidic fibroblast growth factor) Angiostatin
Angiogenin a2-makroglobulin
Ang-1 (angiopoietin 1) Platelet factor 4
Ang-2 (angiopoietin 2) Endostatin
b-FGF (basic fibroblast growth factor) Interferon a
Chemokin SDF-1 Interferon b
Eph A (ephrin-A) Interferon g
Eph B (ephrin-B) Interleukin 12
Fibrin-derived peptide beta 15–42 N-terminal prolactin 
fragment
G-CSF (granulocyte colony stimulating 
factor)









PDGF (platelet-derived growth factor)
PGE1 (prostaglandin E1)
PGE2 (prostaglandin E2)
PIGF (placental growth factor)
PLF (proliferin)
TGF-b (transforming growth factor beta)
TNF-a (transforming growth factor 
alpha)
VEGF (vascular endothelial growth 
factor)
substances in the serum and their expressions in the 
tumour tissue, determining the number, density, and 
morphology of tumour vessels, but also counting the 
number of vascular endothelial progenitor cells in the 
blood. Initially, research concentrated on carrying out 
microscopic examinations of the cancerous tissue; sub-
sequently, histochemical evaluation of the microvessel 
density (MVD) and factors regulating the expression of 
angiogenesis in the neoplastic tissues was performed. 
For reasons of easy access, and quick and reproducible 
results, enzyme-linked immunoassay (ELISA) is often 
used as a reliable method for measuring concentrations 
of proangiogenic and anti-angiogenic cytokines in 
blood serum. In addition, expression of genes respon-
sible for the production of angiogenic tumour cells 
may be examined by RT-PCR (reverse transcription 
polymerase chain reaction). Growing availability of flow 
cytometry permits quantification of vascular endothelial 
progenitor cells in the blood. Circulating vascular en-
dothelial progenitor cells (CEPC) are precursor cells 
derived from bone marrow, which shows proliferative 
potential. These cells are involved in the process of 
postnatal vasculogenesis. They form the base for the 
development of new vessels as a building material, but 
also stimulating adjacent cells by the paracrine effect. 
It is suspected that the endothelial progenitor cells 
play a role in the formation of blood vessels in tumours 
too. A summary of the methods used in the studies on 
angiogenesis is shown in Table 2.
Hodgkin’s lymphoma overview
Hodgkin’s lymphoma (HL) is a neoplastic disease of 
the lymphatic system characterised by the presence of 
polynuclear Reed-Sternberg and Hodgkin cells (HRS). 
These cells induce proliferation of lymphocytes, mono-
cytes, macrophages, and histiocytes. There are two 
main types of HL: classical HL (95%) and nodular lym-
phocyte predominant HL (5%). The morbidity due to HL 
in developed countries is about 2–3 per 100,000/year. 
In 2010, in Poland, more than 700 new cases were 
diagnosed with HL, representing approximately 0.5% 
of malignant tumours. Most cases of HL are diagnosed 
in people aged between 15 and 40 years [8]. There are 
no clearly defined risk factors, although it has been 
suggested that genetic predisposition, viral infections 
(EBV), and immunosuppression can increase individual 
chances of developing this disease [9]. The elements 
of a routine evaluation are staging and assessing prog-
nostic factors [10, 11].
Treatment of HL
Treatment includes radiation therapy, chemo-
therapy, or sequence of both methods. The first-line 
treatment regimens used in adult patients are ABVD 
(doxorubicin, bleomycin, vinblastine, dacarbazine) and 
BEACOPP (bleomycin, etoposide, doxorubicin, cyclo-
phosphamide, vincristine, procarbazine, prednisone). 
The majority of patients can be cured as a result of such 
treatment. The cure rate reaches 80% [9]. Anti-angio-
genic drugs are not routinely used in the treatment of 
this disease, but studies using animal models of HL in-
dicate that some drugs may act synergistically involving 
the inhibition of angiogenesis [12].
Prognostic factors in HL
One of the directions of research on HL is studying 
substances with the potential to be new prognostic 
factors. In the future, this could lead to the identification 
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Table 2. Methods used in studies concerning angiogenesis
Morphological studies Studies on the expression 
of proangiogenic and 
antiangiogenic factors
Studies on the serum 
levels of proangiogenic 
and antiangiogenic 
factors
Studies on the levels 




characteristics based on 
classical HE staining and 
immunostaining:
•	 number of the vessels
•	 vascular density
•	morphology of the vessels
Immunohistochemical studies of 
the neoplastic tissue
Concentrations of VEGF, 
PDGF, HGF, sVEGFR1, 
sVEGFR2, etc. 
Amount of CEPC in the 
blood using the panel of 
antibodies against specific 
cell antigens
Microvessel density and 
microvessel density to total 
vascular area ratio (MVD/TVA)
Molecular biology techniques 
(reverse transcription polymerase 
chain reaction (RT-PCR)
of groups of patients who should be considered for re-
duction of treatment intensity in order to avoid the side 
effects associated with oncological treatment, or the use 
of a more aggressive therapeutic approach in patients 
at high risk of relapse. The observation that high levels 
of VEGF in the blood serum HL are associated with 
a poor prognosis suggests that VEGF may be a new 
prognostic factor [13, 14].
Role of the characteristics of 
microcirculation in tumour tissue
Studies on vascular morphology HL showed in-
creased vessel diameter with increasing stage of the 
disease, but microvascular density (MVD) was found to 
be reduced with more advanced stage. It is speculated 
that this is due to the predominant effect of factors 
stimulating the differentiation of blood vessels, such as 
angiopoietin-1 and 2 and metalloproteinases, over the 
factors promoting the formation of new blood vessels 
such as VEGF, bFGF (basic fibroblast growth factor), 
and HGF (hepatic growth factor) [15]. In addition, it has 
been shown that the severity of angiogenesis examined 
on the basis of MVD/TVA (total vascular area) adversely 
affects the prognosis [16].
Role of expression of proangiogenic 
factors
Studies using immunohistochemistry have demon-
strated the expression of several factors influencing 
angiogenesis. These include VEGF, FGF1 (fibroblast 
growth factor 1), FGF2 (fibroblast growth factor 2; ba-
sic fibroblast growth factor), FGFR2 (type 2 receptor 
for fibroblast growth factor), FGFR3 receptor (type 
3 for fibroblast growth factor), PDGFRa (receptor for 
platelet-derived growth factor), HIF-1a (hypoxia induc-
ible factor 1), matrix metalloproteinases (MMP2 and 
MMP9), as well as tissue inhibitor of metalloproteinase 
(TIMP) [15, 17–19]. In another study, the expression of 
VEGF was demonstrated, while expression of PDGF 
increased with disease progression as MVD [20]. Stud-
ies of receptor expression for pro-angiogenic factors 
on HRS cells are few but indicate a high percentage 
of VEGFR-1 and VEGFR-2 in HRS cells, lymphocytes, 
and histiocytes [21, 22].
Data on the process of angiogenesis in HL are scarce, 
and the results of studies are often contradictory. The po-
tential of HRS cells to stimulate angiogenesis was shown 
in in vitro studies [17, 23]. HRS cells not only produce but 
also have the ability to secrete VEGF [17]. Another study 
found over-expression of FGF-2 in these cells, and this 
was confirmed by the study of RT-PCR [23].
Role of the microenvironment
The enumerated substances are known to stimulate 
angiogenesis factors and are secreted by HRS tumour 
cells. However, these cells constitute only about 1% of 
the tumour. The majority of the cells constitute reactive 
lymphocytes, eosinophils, macrophages, mast cells, 
plasma cells, fibroblasts, and others. Perhaps the 
effect on angiogenesis in this disease is not only the 
consequence of the direct stimulation of the process by 
cancer cells but also an indirect result of the interaction 
of the cells with the HRS microenvironment. The survival 
and proliferation of HRS cells depend not only on the ge-
netic changes but also on the interaction of these cells 
with the microenvironment. This type of dependency 
is mediated by the secretion of inflammatory cytokines 
and chemokines by the cells of the HL, as well as by the 
protection of the tumour cells from elimination by the 
immune system. Animal studies suggest that mast cells 
of the microenvironment HL promote neovascularisation 
and fibrosis, which can be inhibited by bortezomib [21].
Infiltration of the inflammatory cells in HL can sup-
port tumour growth and neovascularisation. Macro-
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phage infiltration appears to be particularly interesting. 
A significant correlation between the expression of 
CD163 (a marker of monocytes and macrophages) 
and MVD is documented, suggesting that tumour- 
-associated macrophages can enhance angiogenesis 
and deteriorate the prognosis [24]. Another study 
showed that there is no effect of mast cell infiltrations 
on the number of microvessels [25]. Some of the known 
factors that promote angiogenesis, like HGF, can be 
expressed in the cell microenvironment and directly 
stimulate cell growth HRS [26]. Factors associated 
with angiogenesis may be linked with the generation of 
a protective immunological environment for neoplastic 
cells. For example, TGF-b inhibits cytotoxic T-lympho-
cytes, and PGE-2 reduces T-cell activation [26].
Serum concentrations of proangiogenic 
substances
The concentration of certain angiogenic substances, 
such as VEGF, bFGF, and HGF, is significantly elevated 
in patients with HL [27–31]. Augmented levels of VEGF 
and bFGF were reduced due to effective treatment, 
but both pre- and post-treatment high levels affect the 
survival of the patients [27]. High levels of VEGF were 
associated with a higher stage of the disease [28]. The 
persistently elevated level of VEGF in patients with HL 
even after achieving a complete remission compared 
to the levels in healthy subjects is an interesting obser-
vation [29]. VEGF levels may be different for different 
subtypes of HL; higher values were observed in classical 
HL compared to patients with nodular lymphocyte-pre-
dominant HL [30]. In another study, it was shown that 
VEGF-C was significantly higher compared to the levels 
in healthy subjects, indicating that this isoform partici-
pates in the stimulation of angiogenesis in HL [31].
Circulating vascular endothelial 
progenitor cells
The correlation between the number of circulating 
vascular endothelial progenitor cells (CEPC) and the 
degree of advancement in non-Hodgkin’s lymphoma 
has been demonstrated; however, the data referring to 
HL in this respect are still non-existent [32]. The role of 
this cell population in the process of angiogenesis and 
progression of HL still remain unidentified.
Inhibition of angiogenesis as 
a therapeutic target in HL
Clinical trials using inhibitors of angiogenesis in 
cancer are focused on the pharmacological modi-
fication of this process at many different steps. The 
main groups of antiangiogenic drugs used in cancer 
treatment include antagonists of the angiogenic factors 
(anti-VEGF monoclonal antibodies, soluble receptors 
for VEGF), blockers of receptor signalling (for VEGFR2 
or PDGFR), endogenous angiogenesis inhibitors (an-
giostatin, endostatin), metalloproteinase inhibitors, and 
anti-inflammatory drugs [33]. Antibodies to VEGF are 
a typical example of anti-angiogenic therapy but are 
not routinely used in the treatment of HL. Drugs such 
as thalidomide, lenalidomide, bortezomib, and histone 
deacetylase inhibitors may also have their effects by 
inhibition of angiogenesis. These drugs have been 
studied in patients with relapsed HL with moderate 
activity [32].
Concluding remarks
An overview of the research points to the importance 
of angiogenesis in the pathogenesis of HL. Activation of 
the VEGF-VEGFR axis may affect both the survival and 
proliferation of lymphoma cells. Recent studies indicate 
an important role of the circulating receptors VEGF-A or 
sVEGFR1 and sVEGFR2 as natural inhibitors of angio-
genesis involved in the control of the angiogenic potential 
of the blood of patients with cancer. The analysis of the 
literature indicates that there are no data concerning the 
levels of sVEGFR1 and sVEGFR2 in the blood of patients 
with HL. Details of the effect of the lymphangiogenesis 
phenomenon on the biology of the HL are still unknown. 
Elements of the angiogenesis regulating system are 
of interest as potential prognostic factors, and the identi-
fication of these factors may in the future have an impact 
on the decisions to intensify or reduce the intensity of 
treatment in individual cases. The presented review of 
studies on the angiogenesis suggests that the balance 
between proangiogenic and anti-angiogenic factors in 
the HL can be moved toward the growth of new blood 
vessels. The information provided in this article sug-
gests that further research is needed to evaluate the 
mechanisms regulating angiogenesis in this disease.
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